Literature DB >> 21407258

Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG).

C M Laine1, B D Chung, M Susic, T Prescott, O Semler, T Fiskerstrand, P D'Eufemia, M Castori, M Pekkinen, E Sochett, W G Cole, C Netzer, O Mäkitie.   

Abstract

Osteoporosis-pseudoglioma sydrome (OPPG) is an autosomal recessive disorder with early-onset severe osteoporosis and blindness, caused by biallelic loss-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) gene. Heterozygous carriers exhibit a milder bone phenotype. Only a few splice mutations in LRP5 have been published. We present clinical and genetic data for four patients with novel LRP5 mutations, three of which affect splicing. Patients were evaluated clinically and by radiography and bone densitometry. Genetic screening of LRP5 was performed on the basis of the clinical diagnosis of OPPG. Splice aberrances were confirmed by cDNA sequencing or exon trapping. The effect of one splice mutation on LRP5 protein function was studied. A novel splice-site mutation c.1584+4A>T abolished the donor splice site of exon 7 and activated a cryptic splice site, which led to an in-frame insertion of 21 amino acids (p.E528_V529ins21). Functional studies revealed severely impaired signal transduction presumably caused by defective intracellular transport of the mutated receptor. Exon trapping was used on two samples to confirm that splice-site mutations c.4112-2A>G and c.1015+1G>T caused splicing-out of exons 20 and 5, respectively. One patient carried a homozygous deletion of exon 4 causing the loss of exons 4 and 5, as demonstrated by cDNA analysis. Our results broaden the spectrum of mutations in LRP5 and provide the first functional data on splice aberrations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21407258      PMCID: PMC3172925          DOI: 10.1038/ejhg.2011.42

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  38 in total

1.  Reduced bone mineral density and hyaloid vasculature remnants in a consanguineous recessive FEVR family with a mutation in LRP5.

Authors:  L M Downey; H M Bottomley; E Sheridan; M Ahmed; D F Gilmour; C F Inglehearn; A Reddy; A Agrawal; J Bradbury; C Toomes
Journal:  Br J Ophthalmol       Date:  2006-09       Impact factor: 4.638

2.  Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13.

Authors:  Y Gong; M Vikkula; L Boon; J Liu; P Beighton; R Ramesar; L Peltonen; H Somer; T Hirose; B Dallapiccola; A De Paepe; W Swoboda; B Zabel; A Superti-Furga; B Steinmann; H G Brunner; A Jans; R G Boles; W Adkins; M J van den Boogaard; B R Olsen; M L Warman
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

3.  Clinical and molecular findings in osteoporosis-pseudoglioma syndrome.

Authors:  Minrong Ai; Shauna Heeger; Cynthia F Bartels; Deborah K Schelling
Journal:  Am J Hum Genet       Date:  2005-09-27       Impact factor: 11.025

4.  Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.

Authors:  V Korinek; N Barker; P J Morin; D van Wichen; R de Weger; K W Kinzler; B Vogelstein; H Clevers
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

5.  Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children.

Authors:  Heini Hartikka; Outi Mäkitie; Minna Männikkö; Andrea S Doria; Alan Daneman; William G Cole; Leena Ala-Kokko; Etienne B Sochett
Journal:  J Bone Miner Res       Date:  2005-01-04       Impact factor: 6.741

6.  Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG).

Authors:  Fahri Bayram; Fatih Tanriverdi; Selim Kurtoğlu; M Emre Atabek; Mustafa Kula; Leyla Kaynar; Fahrettin Keleştimur
Journal:  J Pediatr Endocrinol Metab       Date:  2006-03       Impact factor: 1.634

7.  A family with osteoporosis pseudoglioma syndrome due to compound heterozygosity of two novel mutations in the LRP5 gene.

Authors:  W M W Cheung; L Y Jin; D K Smith; P T Cheung; E Y W Kwan; L Low; A W C Kung
Journal:  Bone       Date:  2006-05-06       Impact factor: 4.398

8.  Missense mutations in LRP5 are not a common cause of idiopathic osteoporosis in adult men.

Authors:  Patricia Crabbe; Wendy Balemans; Andy Willaert; Inge van Pottelbergh; Erna Cleiren; Paul J Coucke; Minrong Ai; Stefan Goemaere; Wim van Hul; Anne de Paepe; Jean-Marc Kaufman
Journal:  J Bone Miner Res       Date:  2005-07-11       Impact factor: 6.741

9.  Osteoporosis-pseudoglioma syndrome: clinical, morphological, and biochemical studies.

Authors:  H Somer; A Palotie; M Somer; V Hoikka; L Peltonen
Journal:  J Med Genet       Date:  1988-08       Impact factor: 6.318

10.  Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia.

Authors:  Anne Saarinen; Tero Saukkonen; Tero Kivelä; Ulla Lahtinen; Christine Laine; Mirja Somer; Sanna Toiviainen-Salo; William G Cole; Anna-Elina Lehesjoki; Outi Mäkitie
Journal:  Clin Endocrinol (Oxf)       Date:  2009-08-05       Impact factor: 3.478

View more
  20 in total

Review 1.  A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice.

Authors:  Kevin A Maupin; Casey J Droscha; Bart O Williams
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

2.  LRP5 and bone mass regulation: Where are we now?

Authors:  Mark L Johnson
Journal:  Bonekey Rep       Date:  2012-01-10

3.  Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG).

Authors:  M Celli; P D'Eufemia; P Persiani; A Turchetti; A Febbo; Y D'Alfonso; L Celli; A Zambrano
Journal:  Osteoporos Int       Date:  2017-09-02       Impact factor: 4.507

Review 4.  WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Authors:  Roland Baron; Michaela Kneissel
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

5.  Strong effect of SNP rs4988300 of the LRP5 gene on bone phenotype of Caucasian postmenopausal women.

Authors:  Péter Horváth; Bernadett Balla; János P Kósa; Bálint Tóbiás; Balázs Szili; Gyöngyi Kirschner; Gabriella Győri; Karina Kató; Péter Lakatos; István Takács
Journal:  J Bone Miner Metab       Date:  2015-03-12       Impact factor: 2.626

6.  Mutations in WNT1 cause different forms of bone fragility.

Authors:  Katharina Keupp; Filippo Beleggia; Hülya Kayserili; Aileen M Barnes; Magdalena Steiner; Oliver Semler; Björn Fischer; Gökhan Yigit; Claudia Y Janda; Jutta Becker; Stefan Breer; Umut Altunoglu; Johannes Grünhagen; Peter Krawitz; Jochen Hecht; Thorsten Schinke; Elena Makareeva; Ekkehart Lausch; Tufan Cankaya; José A Caparrós-Martín; Pablo Lapunzina; Samia Temtamy; Mona Aglan; Bernhard Zabel; Peer Eysel; Friederike Koerber; Sergey Leikin; K Christopher Garcia; Christian Netzer; Eckhard Schönau; Victor L Ruiz-Perez; Stefan Mundlos; Michael Amling; Uwe Kornak; Joan Marini; Bernd Wollnik
Journal:  Am J Hum Genet       Date:  2013-03-14       Impact factor: 11.025

7.  A novel dominant COL11A1 mutation in a child with Stickler syndrome type II is associated with recurrent fractures.

Authors:  M G Vogiatzi; D Li; L Tian; J P Garifallou; C E Kim; H Hakonarson; M A Levine
Journal:  Osteoporos Int       Date:  2017-10-03       Impact factor: 4.507

8.  Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.

Authors:  Rajendra Kedlaya; Shreya Veera; Daniel J Horan; Rachel E Moss; Ugur M Ayturk; Christina M Jacobsen; Margot E Bowen; Chris Paszty; Matthew L Warman; Alexander G Robling
Journal:  Sci Transl Med       Date:  2013-11-13       Impact factor: 17.956

Review 9.  Wnt and the Wnt signaling pathway in bone development and disease.

Authors:  Yiping Wang; Yi-Ping Li; Christie Paulson; Jian-Zhong Shao; Xiaoling Zhang; Mengrui Wu; Wei Chen
Journal:  Front Biosci (Landmark Ed)       Date:  2014-01-01

10.  Osteoporosis-pseudoglioma syndrome in four new patients: identification of two novel LRP5 variants and insights on patients' management using bisphosphonates therapy.

Authors:  Mohamed S Abdel-Hamid; Rasha M Elhossini; Ghada A Otaify; Sherif F Abdel-Ghafar; Mona S Aglan
Journal:  Osteoporos Int       Date:  2022-02-01       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.